Some researchers have conducted large-scale (53 cases) whole-genome sequencing of DFSP for the first time, suggesting that the SLC2A5-BTBD7 fusion gene may be a new potential diagnostic and therapeutic target for DFSP, and detected AKT1 and SPHK1 oncogene amplification and CDKN1A/B gene expression deficiency [19]. This evidence concerns the gene CDKN1A and dermatofibrosarcoma protuberans.